Acute kidney injury in severe pneumonia associated with COVID-19

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The clinical and epidemiological features of acute kidney injury in severe and extremely severe pneumonia associated with coronavirus disease-2019 (COVID-19) are considered. An observational prospective study was conducted with the inclusion of 117 patients, including 75 men and 42 women, suffering from severe and extremely severe pneumonia associated with COVID-19, who were treated in the intensive care unit of the 1586th Military Clinical Hospital in 2020–2022. Acute kidney injury was diagnosed in 21 (17.9%) patients (stage 1 in 10, stage 2 in 4, and stage 3 in 7 patients), kidney dysfunction was recorded in 22 (8.8%) patients (serum creatinine was higher than normal, but does not reach the diagnostic criteria of Kidney Disease Improving Global Outcomes). Four patients underwent renal replacement therapy. The probability of kidney damage increases with age (the average age of the patients with acute kidney damage is 65 (58; 71) years, and those without acute kidney damage was 47.5 (41; 55) years; p = 0.0001). Compared with patients without acute kidney injury, patients with acute kidney injury scored higher on the scales NEW (p = 0.000975), SMRT-CO (p = 0.011555), and Sequential Organ Failure Assessment (p = 0.000042). Among those suffering from acute kidney injury, significantly more pronounced manifestations of systemic inflammation were determined (leukocytes, p = 0.047324; platelets, p = 0.001230; ferritin, p = 0.048614; and D-dimer, p = 0.004496). In the general cohort, the mortality rate was 22.2%, whereas a significant intergroup difference in mortality was observed, i.e., 52.4% in patients with acute kidney injury and 15.62% in those without acute kidney injury (Chi-squared criterion, 13.468; p < 0.001). Invasive artificial lung ventilation was performed in 19.66% of the patients, and a significant intergroup difference was identified, with 66.7% in patients with acute kidney injury and 9.38% in patients without acute kidney injury (Chi-squared criterion, 35.810; p < 0.001). The durations of treatment in the intensive care unit in patients with and without acute kidney injury were 9 (7; 14) and 6 (4; 10) days, respectively. After the treatment, all patients with acute kidney injury had fully recovered kidney function upon discharge. In general, acute kidney injury occurs in almost every fifth patient with severe and extremely severe pneumonia associated with COVID-19, aggravates the condition of patients, and increases mortality. The alertness of doctors regarding acute kidney injury and early diagnosis and timely nephroprotective treatment may reduce the possibility of adverse disease outcomes.

Full Text

Restricted Access

About the authors

Magomedali O. Magomedaliev

1586 Military Clinical Hospital; Moscow Medical and Social Institute named after F.P. Haaz

Author for correspondence.
Email: magomedalim@mail.ru
ORCID iD: 0000-0002-0483-1050

Senior Resident

Russian Federation, Podolsk; Moscow

Daniil I. Korabelnikov

1586 Military Clinical Hospital; Moscow Medical and Social Institute named after F.P. Haaz

Email: dkorabelnikov@mail.ru
ORCID iD: 0000-0002-0459-0488
SPIN-code: 7380-7790
Scopus Author ID: 7801382184

Candidate of Medical Sciences

Russian Federation, Podolsk; Moscow

Sergey E. Khoroshilov

Main Military Clinical Hospital named after Academician N.N. Burdenko

Email: intensive@list.ru
ORCID iD: 0000-0002-0427-8099
SPIN-code: 7071-6642

Doctor of Medical Sciences

Russian Federation, Moscow

References

  1. Burki T. The origin of SARS-CoV-2. Lancet Infect Dis. 2020;20(9):1018–1019. doi: 10.1016/S1473-3099(20)30641-1
  2. Galanopoulos M, Gkeros F, Doukatas A, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020;26(31):4579–4588. doi: 10.3748/wjg.v26.i31.4579
  3. Epidemiology Working Group for NCIP Epidemic Response C.C. for D.C. and P. Vital Surveillances: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Weekly. 2020;2(8):113–122. doi: 10.46234/ccdcw2020.032
  4. Oliveira E, Parikh A, Lopez-Ruiz A, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS One. 2021;16(3):e0249038. doi: 10.1371/journal.pone.0249038
  5. Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8(5):506–517. doi: 10.1016/S2213-2600(20)30161-2
  6. Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–1434. doi: 10.1164/rccm.202003-0736LE
  7. Shovlin CL, Vizcaychipi MP. Implications for COVID-19 triage from the ICNARC report of 2204 COVID-19 cases managed in UK adult intensive care units. Emerg Med J. 2020;37(6):332–333. doi: 10.1136/emermed-2020-209791
  8. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052. doi: 10.1001/jama.2020.6775
  9. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239. doi: 10.1001/jama.2020.2648
  10. Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94: 128–132. doi: 10.1016/j.ijid.2020.03.053
  11. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). JAMA. 2020;324(8):782. doi: 10.1001/jama.2020.12839
  12. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838. doi: 10.1016/j.kint.2020.03.005
  13. Yildirim C, Ozger HS, Yasar E, et al. Early predictors of acute kidney injury in COVID-19 patients. Nephrology. 2021;26(6):513–521. doi: 10.1111/nep.13856
  14. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter Suppl. 2012;1:1–126.
  15. Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12(1):2506. doi: 10.1038/s41467-021-22781-1
  16. Chen Y-T, Shao SC, Hsu CK, et al. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Crit Care. 2020;24(1):346. doi: 10.1186/s13054-020-03009-y
  17. Lowe R, Ferrari M, Nasim-Mohi M, et al. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol. 2021;22(1):92. doi: 10.1186/s12882-021-02296-z
  18. Perico L, Benigni A, Remuzzi G. Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. Curr Opin Nephrol Hypertens. 2021;30(2):252–263. doi: 10.1097/MNH.0000000000000692
  19. Shatunova PO, Bykov AS, Svitich OA, Zverev VV. Angiotensin-converting enzyme 2. Approaches to pathogenetic therapy of COVID-19. Journal of Microbiology, Epidemiology and Immunobiology. 2020;97(4):339–345. (In Russ.) doi: 10.36233/0372-9311-2020-97-4-6
  20. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–227. doi: 10.1016/j.kint.2020.04.003
  21. Jones M. NEWSDIG: The National Early Warning Score Development and Implementation Group. Clin Med J. 2012;12(6): 501–503. doi: 10.7861/clinmedicine.12-6-501
  22. Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia. Clin Infect Dis. 2008;47(3): 375–384. doi: 10.1086/589754
  23. Vincent J-L, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707–710. doi: 10.1007/bf01709751
  24. Qian J-Y, Wang B, Lv L-L, Liu BC. Pathogenesis of Acute Kidney Injury in Coronavirus Disease 2019. Front Physiol. 2021;12:586589. doi: 10.3389/fphys.2021.586589
  25. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus – Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi: 10.1001/jama.2020.1585
  26. Silver SA, Beaubien-Souligny W, Shah PS, et al. The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis. Kidney Med. 2021;3(1):83–98.e1. doi: 10.1016/j.xkme.2020.11.008
  27. Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151–160. doi: 10.1681/ASN.2020050615
  28. Kanbay M, Medetalibeyoglu A, Kanbay A, et al. Acute kidney injury in hospitalized COVID-19 patients. Int Urol Nephrol. 2022;54(5): 1097–1104. doi: 10.1007/s11255-021-02972-x
  29. Pode Shakked N, de Oliveira MHS, Cheruiyot I, et al. Early prediction of COVID-19-associated acute kidney injury: Are serum NGAL and serum Cystatin C levels better than serum creatinine? Clin Biochem. 2022;102:1–8. doi: 10.1016/j.clinbiochem.2022.01.006
  30. Pei G, Zhang Z, Peng J, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020;31(6):1157–1165. doi: 10.1681/ASN.2020030276
  31. Magomedaliev MO, Korabelnikov DI, Khoroshilov SE. Acute kidney injury in patients with pneumonia. Russian Medical and Social Journal. 2019;1(1):59–73. (In Russ.) doi: 10.35571/RMSJ.2019.1.006
  32. Fisher M, Neugarten J, Bellin E, et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. J Am Soc Nephrol. 2020;31(9):2145–2157. doi: 10.1681/ASN.2020040509

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77762 от 10.02.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies